Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin
Joseph W. Po(Camden and Campbelltown Hospitals), Therese M. Becker(Liverpool Hospital), Anna DeFazio(The University of Sydney), David T. Lynch(Mayo Clinic in Arizona), Catherine J. Kennedy(The University of Sydney), Aflah Roohullah, Michelle Harrison(Washington University in St. Louis), Paul R. Harnett(The University of Sydney), Paul de Souza(St. George Hospital)
Cited by 70
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k